PFIZER - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.4
| Stock Code | PFIZER | Market Cap | 21,550 Cr. | Current Price | 4,711 ₹ | High / Low | 5,993 ₹ |
| Stock P/E | 28.3 | Book Value | 841 ₹ | Dividend Yield | 0.74 % | ROCE | 21.6 % |
| ROE | 16.4 % | Face Value | 10.0 ₹ | DMA 50 | 4,820 ₹ | DMA 200 | 4,932 ₹ |
| Chg in FII Hold | 0.10 % | Chg in DII Hold | -0.16 % | PAT Qtr | 182 Cr. | PAT Prev Qtr | 189 Cr. |
| RSI | 44.1 | MACD | -13.0 | Volume | 8,001 | Avg Vol 1Wk | 12,080 |
| Low price | 4,100 ₹ | High price | 5,993 ₹ | PEG Ratio | 17.9 | Debt to equity | 0.01 |
| 52w Index | 32.2 % | Qtr Profit Var | 43.0 % | EPS | 187 ₹ | Industry PE | 30.1 |
📊 Optimal Buy Price (Intraday): ₹4,690–4,710 (near current support, below DMA 50 at ₹4,820)
🎯 Profit-Taking Levels: ₹4,770–4,820 (short-term resistance zone, close to DMA 50)
🛡️ Stop-Loss / Loss Protection: ₹4,660–4,670 (below intraday support)
⏱️ Exit Strategy (If Already Holding): Exit if price fails to sustain above ₹4,670 with rising volume, or book profits near ₹4,770–4,820 if RSI weakens. Extend trades only if breakout volume sustains above ₹4,820.
---
### Positive
- Strong fundamentals: ROCE 21.6% and ROE 16.4% highlight efficient capital use.
- EPS of ₹187 supports valuation strength.
- Debt-to-equity at 0.01 shows negligible leverage risk.
- Dividend yield at 0.74% provides shareholder returns.
- FII holding increased (+0.10%), reflecting marginal foreign investor confidence.
### Limitation
- RSI at 44.1 indicates weak momentum.
- MACD negative (-13.0) suggests bearish bias.
- Current price below DMA 50 (₹4,820) and DMA 200 (₹4,932), showing medium-term weakness.
- PEG ratio at 17.9 highlights expensive growth-adjusted valuation.
- Volume (8,001) below weekly average (12,080), limiting intraday liquidity.
### Company Negative News
- Sequential PAT decline (₹189 Cr. → ₹182 Cr.) shows mild earnings pressure.
- DII holding reduced (-0.16%), reflecting cautious domestic sentiment.
### Company Positive News
- Quarterly profit variation (+43%) highlights strong year-on-year growth.
- 52-week index at 32.2% shows relative price strength despite recent weakness.
### Industry
- Pharma sector benefits from defensive demand and global healthcare growth.
- Industry PE at 30.1 is slightly higher than PFIZER’s P/E (28.3), showing fair valuation relative to peers.
### Conclusion
PFIZER is a moderately strong intraday candidate with solid fundamentals but weak technical momentum. Best suited for disciplined trades between ₹4,690–4,820 with strict stop-loss at ₹4,670. Avoid aggressive positions unless strong breakout volume confirms strength above ₹4,820; risk remains moderate due to high PEG ratio and limited liquidity.
Would you like me to add a sector overlay and peer benchmarking HTML template (Sun Pharma, Dr. Reddy’s, Cipla) so you can compare PFIZER’s intraday setup against pharma peers for workflow clarity?